Navigation Links
Tigris Pharmaceuticals Appoints Pedro Granadillo as Chairman of Board of Directors
Date:4/16/2009

BONITA SPRINGS, Fla., April 16 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held company developing targeted cancer treatment therapies, today announced the appointment of Pedro Granadillo as Chairman of the company's Board of Directors. Mr. Granadillo is a highly-respected pharmaceutical industry leader with over 30 years of experience in corporate management.

"Pedro's appointment as Chairman of the Board of Directors will further expand his leadership role within our company and will play a key role in our partnering efforts and corporate strategy. We are pleased to have such a widely respected and experienced senior pharmaceutical executive chair our Board of Directors," said Edmundo Muniz, Chief Executive Officer of Tigris. "His past experience and proven track record in pharmaceutical drug development will be instrumental as we drive our partnering programs and our clinical programs forward."

"I am excited to be serving as Chairman at this important time in the Company's development," said Mr. Granadillo. "I look forward to working with the management team, the Board and the Company's investors in implementing the Company's strategic initiatives over the next year and beyond."

Mr. Granadillo served as Senior Vice President for Eli Lilly and Company until his retirement in 2004 after 34 years of service. As a member of Lilly's Executive Committee and as Lilly's head of human resources, manufacturing and quality, he was responsible for policies affecting a global workforce of more than 45,000 employees, as well as a broad network of manufacturing facilities for its extensive line of products. Mr. Granadillo led initiatives that brought Lilly wide recognition as a progressive employer. He also oversaw more than 20 sites and 13,000 employees involved in the manufacturing of Lilly's conventional "small-molecule" pharmaceuticals and "large-molecule" biotech therapies.

Mr. Granadillo also currently serves on the boards of directors of Haemonetics Corporation of Braintree, MA; Noven Pharmaceuticals, Miami, FL; and Nile Therapeutics, San Francisco, CA. Mr. Granadillo earned his B.S. degree in Industrial Engineering from Purdue University.

About Tigris Pharmaceuticals, Inc.

Tigris Pharmaceuticals, Inc. is a privately held biopharmaceutical company that develops therapeutic technologies, using a translational research approach, for use in oncology and other areas of unmet medical need. Tigris' mission is to efficiently move its existing and future technologies through the various stages of clinical development in order to meet patients' needs for safe and effective treatments of human illnesses.

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. All statements, other than statements of historical facts, including statements regarding Tigris' strategy, future operations, outlook, and plans and objectives of management, are forward-looking statements. We may not actually achieve these plans, intentions or expectations. Various important factors could cause actual results or events to differ materially from these forward-looking statements, including among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our collaborators' ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies. This information is provided as of the date of this press release and Tigris does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Tigris Pharmaceuticals Appoints Pedro Granadillo to Board of Directors
2. Vion Pharmaceuticals New Drug Application for Onrigin(TM)Accepted For Review by the FDA
3. Generic Pharmaceuticals Offer Exciting Growth Opportunities in Tanzania, Reveals Frost & Sullivan
4. Alseres Pharmaceuticals, Inc. Receives Notice of De-Listing of Its Securities for Failure to Regain Compliance with Continued Listing Requirements
5. Amylin Pharmaceuticals to Webcast First Quarter Results
6. MonoSol Rx and Strativa Pharmaceuticals Submit New Drug Application for Ondansetron Orally Dissolving Film Strip
7. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
8. Sigma-Tau Pharmaceuticals and Danisco BioActives Announce Partnership Agreement to Develop Drug Candidate for Prevention of Necrotizing Enterocolitis
9. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-101, Potent Small Molecule for Treatment of Alzheimers Disease.
10. Jazz Pharmaceuticals, Inc. Announces Board of Directors and Management Changes
11. Genesis Pharmaceuticals Affirms Operating Income Guidance, Adjusts Revenue Guidance for Fiscal 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology: